Past and future of the mitotic spindle as an oncology target

Current Opinion in Pharmacology

Volumn 1, Issue 4, 2001, Pages 370-377

  Wood, Kenneth W ^a   Cornwell, William D ^b   Jackson, Jeffrey R ^b  

^a Cytokinetics Inc   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Anti mitotic therapy; Cell cycle check points; Genetics; Microtubules; Mitotic kinase; Mitotic kinesins; Molocular Medicine; Pharmacology; Taxanes; Tubulin; Vinca alkaloids

Indexed keywords

ANTINEOPLASTIC AGENT; KINESIN; TUBULIN;

ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; MITOSIS SPINDLE; NEOPLASM; PATHOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; KINESIN; MITOTIC SPINDLE APPARATUS; NEOPLASMS; TUBULIN;

EID: 0035433029     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00064-9     Document Type: Review

References (64)

1. Palmer C.G., Livengood D., Warren A.K., Simpson P.J., Johnson I.S. The action of vincaleukoblastine on mitosis in vitro. Exp Cell Res. 20:1960;198-265.
2. Levan A. The effect of colchicine on root mitoses in Allium. Hereditas. 24:1938;471-486.
3. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature. 277:1979;665-667.
4. Schiff P.B., Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA. 77:1980;1561-1565.
5. Mitchison T., Kirschner M. Dynamic instability of microtubule growth. Nature. 312:1984;237-242.
6. Desai A., Mitchison T.J. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol. 13:1997;83-117.
7. Wassmann K., Benezra R. Mitotic checkpoints: from yeast to cancer. Curr Opin Genet Dev. 11:2001;83-90.
8. Woods C.M., Zhu J., McQueney P.A., Bollag D., Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med. 1:1995;506-526.
9. Jordan M.A., Wendell K., Gardiner S., Derry W.B., Copp H., Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56:1996;816-825.
10. Di Leonardo A., Khan S.H., Linke S.P., Greco V., Seidita G., Wahl G.M. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res. 57:1997;1013-1019.
11. Cross S.M., Sanchez C.A., Morgan C.A., Schimke M.K., Ramel S., Idzerda R.L., Raskind W.H., Reid B.J. A p53-dependent mouse spindle checkpoint. Science. 267:1995;1353-1356.
12. Lanni J.S., Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol. 18:1998;1055-1064.
13. Khan S.H., Wahl G.M. p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res. 58:1998;396-401.
14. Waf1/Cip1 under the control of an inducible promoter, to demonstrate that defects in G1 checkpoint proteins can sensitize cells to antimicrotubule agents.
15. Minn A.J., Boise L.H., Thompson C.B. Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev. 10:1996;2621-2631.
16. Haruki N., Saito H., Harano T., Nomoto S., Takahashi T., Osada H., Fujii Y., Takahashi T. Molecular analysis of the mitotic checkpoint genes BUB1, BUBR1 and BUB3 in human lung cancers. Cancer Lett. 162:2001;201-205.
17. Jaffrey R.G., Pritchard S.C., Clark C., Murray G.I., Cassidy J., Kerr K.M., Nicolson M.C., McLeod H.L. Genomic instability at the BUB1 locus in colorectal cancer, but not in non-small cell lung cancer. Cancer Res. 60:2000;4349-4352.
18. Cahill D.P., Lengauer C., Yu J., Riggins G.J., Willson J.K., Markowitz S.D., Kinzler K.W., Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature. 392:1998;300-303.
19. Cahill D.P., da Costa L.T., Carson-Walter E.B., Kinzler K.W., Vogelstein B., Lengauer C. Characterization of MAD2B and other mitotic spindle checkpoint genes. Genomics. 58:1999;181-187.
20. Scolnick D.M., Halazonetis T.D. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature. 406:2000;430-435. This work correlates loss of Chfr function, due to either mutation or loss of expression, in several tumor cell lines with increased sensitivity to mitotic stress induced by several antimicrotubule drugs. Although the biochemical function of Chfr is not described, in the presence of antimicrotubule drugs loss of Chfr was characterized by an inability to restrain cell-cycle progression into prometaphase. These findings will surely prompt a thorough examination of the role of Chfr inactivation in the sensitivity of human cancers to antimicrotubule agents.
21. Cavaletti G., Cavalletti E., Montaguti P., Oggioni N., De Negri O., Tredici G. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology. 18:1997;137-145.
22. Pitot H.C., McElroy E.A. Jr, Reid J.M., Windebank A.J., Sloan J.A., Erlichman C., Bagniewski P.G., Walker D.L., Rubin J., Goldberg R.M., et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 5:1999;525-531.
23. Rowinsky E.K., Chaudhry V., Cornblath D.R., Donehower R.C. Neurotoxicity of Taxol. J Natl Cancer Inst. 15:1993;107-115.
24. Cole S.P., Sparks K.E., Fraser K., Loe D.W., Grant C.E., Wilson G.M., Deeley R.G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 54:1994;5902-5910.
25. Lorico A., Rappa G., Flavell R.A., Sartorelli A.C. Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Res. 56:1996;5351-5355.
26. Samuels B.L., Hollis D.R., Rosner G.L., Trump D.L., Shapiro C.L., Vogelzang N.J., Schilsky R.L. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin Cancer Res. 3:1997;1977-1984.
27. Jordan M.A., Thrower D., Wilson L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci. 102:1992;401-416.
28. Kavallaris M., Kuo D.Y.S., Burkhart C.A., Regl D.L., Norris M.D., Haber M., Horwitz S.B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 100:1997;1282-1293.
29. Giannakakou P., Sackett D.L., Kang Y.K., Zhan Z., Buters J.T., Fojo T., Poruchynsky M.S. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired aclitaxeldriven olymerization. J Biol Chem. 272:1997;17118-17125.
30. Schibler M.J., Barlow S.B., Cabral F. Elimination of permeability mutants from selections for drug resistance in mammalian cells. FASEB J. 3:1989;163-168.
31. Polizzi D., Pratesi G., Tortoreto M., Supino R., Riva A., Bombardelli E., Zunino F. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts. Cancer Res. 59:1999;1036-1040.
32. Polizzi D., Pratesi G., Monestiroli S., Tortoreto M., Zunino F., Bombardelli E., Riva A., Morazzoni P., Colombo T., D'Incalci M., Zucchetti M. Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res. 6:2000;2070-2074.
33. Gelmon K.A., Latreille J., Tolcher A., Genier L., Fisher B., Forand D., D'Aloisio S., Vernillet L., Daigneault L., Lebecq A., et al. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Onc. 18:2000;4098-4108.
34. Gelmon K.A., Tolcher A., Diab A.R., Bally M.B., Embree L., Hudon N., Dedhar C., Ayers D., Eisen A., Melosky B., et al. Phase I study of liposomal vincristine. J Clin Oncol. 17:1999;697-705.
35. Webb M.S., Sarris A.H., Cabanillas F., Mayer L.D., Bally M.B., Burge C., Cullis P.R. Clinical and preclinical pharmacology of liposomal vincristine. J Liposome Res. 10:2000;501-512.
36. Altmann K.H., Wartmann M., O'Reilly T. Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta. 1470:2000;M79-M91.
37. Hamel E., Sackett D.L., Vourloumis D., Nicolaou K.C. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochem. 38:1999;5490-5498.
38. McDaid H.M., Bhattacharya S.K., Chen X.T., He L., Shen H.J., Gutteridge C.E., Horwitz S.B., Danishefsky S.J. Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines. Cancer Chemother Pharmacol. 44:1999;131-137.
39. Cogswell J.P., Brown C.E., Bisi J.E., Neill S.D. Dominant-negative Polo- like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ. 11:2000;615-623. This eport demonstrates that Plk1 has roles in mitosis other than activating cdc25C.The data presented here suggest that loss of cdc25C activation is not sufficient to cause a catastrophic event in mitosis, but Plk1 may be acting elsewhere in mitosis.
40. Smits V.A.J., Klompmaker R., Arnaud L., Rijksen G., Nigg E.A., Medema R.H. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol. 2:2000;672-676.
41. Glover D.M., Hagan I.M., Tavares A.A.M. Polo-like kinases: a team that plays throughout mitosis. Genes Dev. 12:1998;3777-3787.
42. Conn C.W., Hennigan R.F., Dai W., Sanchez Y., Stambrook P.J. Incomplete cytokinesis and induction of apoptosis by overexpression of the mammalian Polo-like kinase, Plk3. Cancer Res. 60:2000;6826-6831.
43. Brady D.M., Hardwick K.G. Complex formation between Mad1p, Bub1p, and Bub3p is crucial for spindle checkpoint function. Curr Biol. 10:2000;675-678. This eport examines the association of Mad1p with Bub1p and Bub3p in yeast. These authors found that Mad1p associated significantly better with Bub1p and Bub3p after the spindle checkpoint was activated. In addition, Mad2p and Mps1p, two other heat shock proteins, were also required for this association to occur. Finally, a conserved motif was identified within Mad1p that was shown to be critical for association of Mad1p with Bub1p and Bub3p; mutation of this motif resulted in the loss of the spindle checkpoint.
44. Farruggio D.C., Townsley F.M., Ruderman J.V. Cdc20 associates with the kinase aurora2/Aik. Proc Natl Acad Sci USA. 96:1999;7306-7311. This tudy is a seminal step to the understanding of APC regulation by mitotic kinases. Although the authors did not definitively show that AIK regulates cdc20 activity, they did demonstrate cdc20 and AIK co-immunoprecipitation. Furthermore, immunoprecipitates of either AIK or cdc20 both contained kinase activity. This evidence may represent the link between AIK and chromosome separation via the APC.
45. Morgan D.O. Regulation of the APC and the exit from mitosis. Nat Cell Biol. 1:1999;E47-E53.
46. Sharp D.J., Rogers G.C., Scholey J.M. Microtubule motors in mitosis. Nature. 407:2000;41-47.
47. Vale R.D., Fletterick R.J. The design plan of kinesin motors. Annu Rev Cell Dev Biol. 13:1997;745-777.
48. Brown K.D., Coulson R.M., Yen T.J., Cleveland D.W. Cyclin-like accumulation and loss of the putative kinetochore motor CENP-E results from coupling continuous synthesis with specific degradation at the end of mitosis. J Cell Biol. 125:1994;1303-1312.
49. Hill E., Clarke M., Barr F.A. The Rab6-binding kinesin, Rab6-KIFL, is required for cytokinesis. EMBO J. 19:2000;5711-5719.
50. Funabiki H., Murray A.W. The Xenopus chromokinesin Xkid is essential for metaphase chromosome alignment and must be degraded to allow anaphase chromosome movement. Cell. 102:2000;411-424. In n elegant series of experiments performed in vitro using Xenopus oocyte extracts, this study nicely demonstrates that Xenopus Kid is a chromosome-associated kinesin that is degraded in anaphase by ubiquitin-mediated proteolysis. The authors further show that depletion of Xenopus Kid results in a defect in prometaphase chromosome alignment, and that an overabundance of Kid can impair anaphase chromosome movement. These findings nicely bracket Kid function in prometaphase, and surely foreshadow similar studies in mammalian cells.
51. Yao X., Anderson K.L., Cleveland D.W. The microtubule-dependent motor centromere-associated protein E (CENP-E) is an integral component of kinetochore corona fibers that link centromeres to spindle microtubules. J Cell Biol. 139:1997;435-447.
52. Schaar B.T., Chan G.K., Maddox P., Salmon E.D., Yen T.J. CENP-E function at kinetochores is essential for chromosome alignment. J Cell Biol. 139:1997;1373-1382.
53. Yao X., Abrieu A., Zheng Y., Sullivan K.F., Cleveland D.W. CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nat Cell Biol. 2:2000;484-491.
54. Chan G.K., Schaar B.T., Yen T.J. Characterization of the kinetochore binding domain of CENP-E reveals interactions with the kinetochore proteins CENP-F and hBUBR1. J Cell Biol. 143:1998;49-63.
55. Abrieu A., Kahana J.A., Wood K.W., Cleveland D.W. CENP-E as an essential component of the mitotic checkpoint in vitro. Cell. 102:2000;817-826. This tudy uses Xenopus oocyte extracts to examine the role of CENP-E in regulation of the metaphase checkpoint. The authors found that immunodepletion of CENP-E prevented cell-cycle arrest induced by the microtubule toxin nocodazole. Furthermore, absence of CENP-E was found to prevent nocodazole-induced binding of Mad2 and Mad1 to kinetochores. An excess of Mad2 could restore nocodazole-induced arrest, despite the absence of CENP-E. The results of this study stand in apparent contrast with those of similar studies in mammalian cells [53]. Both studies reinforce the role of CENP-E as a pivotal player in checkpoint regulation, and the discussion in this paper of the paradoxical findings is informative and thought-provoking.
56. Yucel J.K., Marszalek J.D., McIntosh J.R., Goldstein L.S., Cleveland D.W., Philp A.V. CENP-meta, an essential kinetochore kinesin required for the maintenance of metaphase chromosome alignment in Drosophila. J Cell Biol. 150:2000;1-11.
57. Sakowicz R., Berdelis M.S., Ray K., Blackburn C.L., Hopmann C., Faulkner D.J., Goldstein L.S. A marine natural product inhibitor of kinesin motors. Science. 280:1998;292-295.
58. Mayer T.U., Kapoor T.M., Haggarty S.J., King R.W., Schreiber S.L., Mitchison T.J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 286:1999;971-974. This landmark paper describes the identification of a specific inhibitor of the mitotic kinesin Eg5. Using a cell-based screen for antimitotic compounds in a library of ~16 000 small molecules the authors identified several compounds. One of these caused mitotic arrest with a monopolar mitotic spindle, a phenotype previously observed following antibody-mediated disruption of Eg5. The action of this compound, called monasterol, towards Eg5 was confirmed in vitro, although the biochemical mechanism of monasterol action is not described. Monasterol did not affect the activity of kinesin heavy chain. Monasterol is the first inhibitor of a specific kinesin to be identified, and has begun to be utilized as a tool to investigate mitotic spindle function and checkpoint signaling (see annotation to [60••]).
59. Blangy A., Lane H.A., d'Herin P., Harper M., Kress M., Nigg E.A. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell. 83:1995;1159-1169.
60. Kapoor T.M., Mayer T.U., Coughlin M.L., Mitchison T.J. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol. 150:2000;975-988. This study used monasterol to assess the response of the metaphase checkpoint protein Mad2 to mitotic arrest in response to a novel pharmacological antimitotic perturbation. Mad2 was found to localize to kinetochores of bi-oriented chromosomes arrayed on a monopolar mitotic spindle. This observation is directly relevant to the longstanding issue of whether the metaphase checkpoint senses kinetochore attachment or chromosome alignment, and suggests that simple attachment is insufficient to satisfy the checkpoint.
61. Rice S., Lin A.W., Safer D., Hart C.L., Naber N., Carragher B.O., Cain S.M., Pechatnikova E., Wilson-Kubalek E.M., Whittaker M., et al. A structural change in the kinesin motor protein that drives motility. Nature. 402:1999;778-784. This remarkable study combines several different experimental approaches to demonstrate the substantial structural change in the 'neck' region of kinesin heavy chain that is responsible for force production, directionality and processive movement along microtubules.
62. Hopkins S.C., Vale R.D., Kuntz I.D. Inhibitors of kinesin activity from structure-based computer screening. Biochem. 39:2000;2805-2814. This study reflects the maturity of kinesin biochemistry, biophysics and structural biology. The authors identify a low micromolar inhibitor of kinesin heavy chain by computational docking of commercially available compounds into its 3-dimensional structure.
63. Goldspiel B.R. Clinical overview of the taxanes. Pharmacotherapy. 17:1997;1105-1255.
64. Budman D.R. Vinorelbine (Navelbine): A third generation vinca alkaloid. Cancer Invest. 15:1997;475-490.